Dunsire out as Takeda rolls Millennium into its global R&D operations

More changes are afoot at Takeda Pharmaceutical, which has been revamping in light of the patent loss of its central drug, diabetes treatment Actos, FierceBiotech reports. CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization. Dunsire's CEO position was eliminated in that move. Her responsibilities will be assumed by her business development chief, Anna Protopapas. The Japanese drugmaker revealed the management shakeup in a terse announcement today about the unit, developer of the cancer treatment Velcade. Story | More

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.